Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that myeloablative hematopoietic progenitor cell
transplantation (HPCT) continues to offer acceptable disease-free survival for select
patients requiring HPCT.
Phase:
Phase 3
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago